TVARDI THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
TVARDI THERAPEUTICS, INC. (TVRD) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 364.12 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 208.64K shares.
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2014-06-30 was 0.00 shares.
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2013-06-30 was 0.00 shares.
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 364.12K shares.
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 0.00 shares.
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 0.00 shares.
- TVARDI THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2013 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2025-12-31 | 364.12K shares 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 486.83K shares 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | 208.64K shares 10-Q · filed 2026-08-14 | 734.28K shares 10-Q · filed 2026-08-14 | ||
| 2015-12-31 | 0.00 shares 10-K · filed 2016-03-11 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2016-03-11 | |||
| 2014-06-30 | 0.00 shares 10-Q · filed 2014-08-07 | 0.00 shares 10-Q · filed 2014-08-07 | ||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-03-11 | |||
| 2013-06-30 | 0.00 shares 10-Q · filed 2014-08-07 | 0.00 shares 10-Q · filed 2014-08-07 | ||
| 2012-12-31 | 0.00 shares 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |